C7287
Canrenoic acid potassium salt
powder
Sinónimos:
17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid, Potassium canrenoate
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula lineal:
C22H30O4K
Número de CAS:
Peso molecular:
397.57
Número CE:
Número MDL:
Código UNSPSC:
12352106
ID de la sustancia en PubChem:
NACRES:
NA.77
Productos recomendados
Formulario
powder
Nivel de calidad
color
light yellow to tan
cadena SMILES
[K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C
InChI
1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1
Clave InChI
YLXFIHIYNGPPSF-HUHWECDNSA-N
Categorías relacionadas
Aplicación
Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.
Acciones bioquímicas o fisiológicas
Competitive aldosterone receptor antagonist.
Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.
Calidad
Aqueous solutions may contain some insoluble material.
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Rita Berardelli et al.
European journal of endocrinology, 162(6), 1067-1074 (2010-03-12)
Mineralocorticoid receptors (MRs) in the hippocampus display an important role in the control of the hypothalamic-pituitary-adrenal (HPA) axis, mediating the proactive feedback of glucocorticoids, which maintains the basal HPA activity. The systemic administration of MR antagonists enhances spontaneous and CRH-stimulated
Helen C Atkinson et al.
American journal of physiology. Endocrinology and metabolism, 294(6), E1011-E1022 (2008-03-20)
The aim of this study was to investigate fast corticosteroid feedback of the hypothalamic-pituitary-adrenal (HPA) axis under basal conditions, in particular the role of the mineralocorticoid receptor. Blood samples were collected every 5 min from conscious rats at the diurnal
Wenxia Chai et al.
Journal of hypertension, 28(5), 1044-1053 (2010-02-25)
To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma. Both corticosterone and aldosterone increased left ventricular pressure in the
Christian J Steib et al.
Gut, 59(6), 827-836 (2010-06-17)
This study aimed to investigate the effect of amiloride on portal hypertension. Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells. Liver cirrhosis in rats was induced by bile duct ligation (BDL) or thioacetamide (TAA) administration. The
Katharina Schmidt et al.
European heart journal, 31(13), 1655-1662 (2009-12-24)
Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico